NASDAQ:SAVA Cassava Sciences (SAVA) Stock Price, News & Analysis $31.42 +0.21 (+0.67%) (As of 10:47 AM ET) Add Compare Share Share Today's Range$30.63▼$31.5550-Day Range$9.57▼$35.0852-Week Range$8.79▼$42.20Volume228,697 shsAverage Volume1.73 million shsMarket Capitalization$1.51 billionP/E RatioN/ADividend YieldN/APrice Target$119.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cassava Sciences alerts: Email Address Cassava Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside281.3% Upside$119.00 Price TargetShort InterestBearish39.67% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment-0.13Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.70) to $0.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.03 out of 5 starsMedical Sector328th out of 924 stocksPharmaceutical Preparations Industry144th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCassava Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Cassava Sciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted39.67% of the outstanding shares of Cassava Sciences have been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Cassava Sciences has recently increased by 17.98%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cassava Sciences is -0.82. Previous Next 1.6 News and Social Media Coverage News SentimentCassava Sciences has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cassava Sciences this week, compared to 5 articles on an average week.Search InterestOnly 56 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows31 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 55% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Cassava Sciences is held by insiders.Percentage Held by InstitutionsOnly 38.05% of the stock of Cassava Sciences is held by institutions.Read more about Cassava Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cassava Sciences are expected to grow in the coming year, from ($5.70) to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -14.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -14.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 7.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cassava Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsWanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Cassava Sciences Stock (NASDAQ:SAVA)Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Read More SAVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAVA Stock News HeadlinesAugust 10, 2024 | marketbeat.comCassava Sciences: A Hot Stock to Trade, Invest, or Avoid?Cassava Sciences has become a hot topic among traders due to its recent surge in volatility, liquidity, and overall market performance.August 19 at 11:39 PM | seekingalpha.comCassava Sciences: Volatility Provides Trading OpportunitiesAugust 22, 2024 | TradingTips (Ad)Buy these “two-bagger” stocksWe’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable.August 18, 2024 | msn.comSilicon Motion Technology Corporation (SAVA): Evaluating Its Position Among Top Debt-Free StocksAugust 16, 2024 | americanbankingnews.comHC Wainwright Research Analysts Reduce Earnings Estimates for Cassava Sciences, Inc. (NASDAQ:SAVA)August 13, 2024 | markets.businessinsider.comCautious Optimism Amidst Legal Challenges: Hold Rating on Cassava SciencesAugust 13, 2024 | americanbankingnews.comCassava Sciences (NASDAQ:SAVA) Receives Neutral Rating from HC WainwrightAugust 12, 2024 | americanbankingnews.comCassava Sciences (NASDAQ:SAVA) Receives "Buy" Rating from Rodman & RenshawAugust 22, 2024 | TradingTips (Ad)Buy these “two-bagger” stocksWe’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable.August 9, 2024 | markets.businessinsider.comJonesTrading Keeps Their Hold Rating on Cassava Sciences (SAVA)August 9, 2024 | benzinga.comBehind the Scenes of Cassava Sciences's Latest Options TrendsAugust 9, 2024 | msn.comCassava Sciences, Inc. (NASDAQ:SAVA) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comCassava Sciences down 15% following $40M loss contingency to resolve SEC probeAugust 8, 2024 | seekingalpha.comCassava Sciences: New CEO, Same Old ProblemsAugust 8, 2024 | seekingalpha.comCassava Sciences Q2 Earnings Review: So Many Questions, So Few AnswersAugust 8, 2024 | markets.businessinsider.comCassava Sciences Reports Q2 2024 Financial Results and Operational UpdatesAugust 8, 2024 | msn.comCassava Sciences estimates $40M loss contingency to resolve SEC simufilam probeAugust 7, 2024 | nasdaq.comMarket Whales and Their Recent Bets on SAVA OptionsSee More Headlines Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today8/22/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SAVA CUSIPN/A CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$119.00 High Stock Price Target$131.00 Low Stock Price Target$107.00 Potential Upside/Downside+284.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-88.23% Return on Assets-68.31% Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book9.49Miscellaneous Outstanding Shares47,980,000Free Float43,658,000Market Cap$1.48 billion OptionableOptionable Beta-0.57 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Remi Barbier (Age 64)Founder, Chairman, President & CEO Comp: $1.2MMr. Eric J. Schoen (Age 56)Chief Financial Officer Comp: $460kMr. R. Christopher Cook (Age 60)Senior VP, Company Secretary & General Counsel Comp: $425kDr. James W. Kupiec M.D. (Age 71)Chief Medical Officer Comp: $435kDr. George Thornton Ph.D.Senior Vice President of TechnologyMr. Michael ZamlootSenior Vice President of Technical OperationsDr. Michael Marsman Pharm.D.Senior Vice President of Regulatory AffairsDr. Lindsay H. Burns Ph.D.Senior Vice President of NeuroscienceMore ExecutivesKey CompetitorsCollegium PharmaceuticalNASDAQ:COLLNature's Sunshine ProductsNASDAQ:NATRVerrica PharmaceuticalsNASDAQ:VRCAVerastemNASDAQ:VSTMChimerixNASDAQ:CMRXView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 288,700 shares on 8/16/2024Ownership: 0.000%Perceptive Advisors LLCBought 183,000 shares on 8/16/2024Ownership: 0.000%The Manufacturers Life Insurance Company Bought 2,377 shares on 8/15/2024Ownership: 0.047%Dark Forest Capital Management LPBought 10,635 shares on 8/15/2024Ownership: 0.022%Profund Advisors LLCBought 591 shares on 8/14/2024Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions SAVA Stock Analysis - Frequently Asked Questions How have SAVA shares performed this year? Cassava Sciences' stock was trading at $22.51 at the beginning of the year. Since then, SAVA shares have increased by 38.6% and is now trading at $31.21. View the best growth stocks for 2024 here. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) released its quarterly earnings results on Thursday, August, 8th. The company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.57. When did Cassava Sciences' stock split? Cassava Sciences's stock split on Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly created shares were payable to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. Who are Cassava Sciences' major shareholders? Top institutional investors of Cassava Sciences include Susquehanna International Group LLP, Perceptive Advisors LLC, Clear Creek Financial Management LLC (0.30%) and Bank of New York Mellon Corp (0.29%). Insiders that own company stock include Eric Schoen and James William Kupiec. View institutional ownership trends. How do I buy shares of Cassava Sciences? Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO) and DURECT (DRRX). This page (NASDAQ:SAVA) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
